A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T77129 | Belantamab | 2061894-48-0 | 98% |
Belantamab
|
Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used t... | ||||
T77125 | Otilimab | 1638332-55-4 | 98% |
Otilimab
|
Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activi... | ||||
T77124 | Osocimab | 2056878-75-0 | 98% |
Osocimab
|
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition... | ||||
T77122 | Praluzatamab | 2145109-70-0 | 98% |
Praluzatamab
|
Praluzatamab is a monoclonal antibody targeting an activated white blood cell adhesion molecule (ALCAM/CD116). Praluzatamab is a naked antibody to Praluzatamab r... | ||||
T77118 | Plozalizumab | 1610761-46-0 | 98% |
|
Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of malignant... | ||||
T77100 | Nirsevimab | 1989556-22-0 | 98% |
Nirsevimab
|
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region. Nirsevimab efficiently targets RSV-... | ||||
T77099 | Nimacimab | 2098636-09-8 | 98% |
Nimacimab
|
Nimacimab is a recombinant humanized monoclonal antibody. It can improve diabetes and non-alcoholic steatohepatitis. | ||||
T77093 | Theralizumab | 906068-56-2 | 98% |
Theralizumab
|
Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the tr... | ||||
T77092 | Nadecnemab | 98% |
Nadecnemab
|
|
Nadecnemab is an IGG4-κantibody targeting GFRA3, a receptor of the glial cell-derived neurotrophic factor family. Nadecnemab can be used for knee osteoarthritis ... | ||||
T77075 | Spartalizumab | 1935694-88-4 | 98% |
Spartalizumab
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that selectively binds to PD-1 at low concentrations and shows high activity. Spartali... | ||||
T77059 | Leronlimab | 674782-26-4 | 98% |
Leronlimab
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. leronlimumab has both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 vir... | ||||
T77054 | Lecanemab | 1260393-98-3 | 98% |
Lecanemab
|
Lecanemab (BAN-2401), an IgG1 monoclonal antibody targeting soluble aggregated amyloid beta (Aβ), demonstrates efficacy across Aβ oligomers, protofibrils, and in... | ||||
T77053 | Latozinemab | 98% |
Latozinemab
|
|
Latozinemab (AL001) is a potent and selective recombinant humanized monoclonal antibody against Sortilin.Latozinemab has a high affinity for Sortilin and interru... | ||||
T77045 | Itepekimab | 2226742-52-3 | 98% |
|
Itepekimab (REGN-3500) is a potent monoclonal antibody against IL-33.Itepekimab reduces airway inflammation and associated tissue damage in in vivo experiments a... | ||||
T77042 | Aducanumab | 1384260-65-4 | 98% |
Aducanumab
|
Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brai... | ||||
T77019 | Garetosmab | 2097125-54-5 | 98% |
Garetosmab
|
Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cance... | ||||
T77018 | Garadacimab | 2162134-62-3 | 98% |
Garadacimab
|
Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioe... | ||||
T77011 | Flanvotumab | 1188277-05-5 | 98% |
|
Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody directed against tyrosinase-related protein (TYRP1).Flanvotumab exhibits potent antitumor activity and... | ||||
T76992 | Suptavumab | 1629615-23-1 | 98% |
Suptavumab
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab neutralizes conserved epitopes on subtypes A and B on RSV. Suptavumab can be used to study RSV i... | ||||
T76978 | Siltuximab | 541502-14-1 | 98% |
Siltuximab
|
Siltuximab(CNTO-328) is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19. |